If you've been searching the research peptide market or following the development of next-generation incretin agonists, you've likely encountered both terms: GLP-3 RT and retatrutide. The short answer is that they refer to the same molecule. The longer answer involves how research peptide catalog names map to international nonproprietary names, why two parallel naming systems exist, and what each means for researchers sourcing material for laboratory and in-vitro studies.
This guide is written for researchers and laboratory buyers evaluating GLP-3 RT (retatrutide) for research-use-only applications. All discussion is framed in the context of preclinical and in-vitro investigation. No claim about therapeutic effects in humans or animals is made or implied.
What GLP-3 RT and Retatrutide Refer To
Retatrutide is a synthetic 39-amino-acid peptide engineered as a triple agonist of the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. The molecule is currently in late-stage clinical investigation under its international nonproprietary name (INN), "retatrutide", which was assigned by the World Health Organization to ensure that the molecule has a single unambiguous identifier across regulatory and clinical research contexts worldwide.
GLP-3 RT is the parallel naming convention used by research peptide suppliers in the United States. The abbreviation reflects the underlying mechanism: GLP-3 conveys that the molecule belongs to the next generation of glucagon-like peptide therapeutics (after the established GLP-1 receptor agonists like semaglutide and the dual GLP-1/GIP agonists like tirzepatide), and the RT suffix derives directly from the first two letters of retatrutide. Both names describe the same chemical entity with the same amino acid sequence, the same C20 diacid fatty acid modification, the same molecular weight (~4937 Da), and the same triple receptor pharmacology.
The reason both names persist is regulatory and operational. Clinical research and prescribing use the INN. Research peptide suppliers operating under Research Use Only (RUO) labeling use catalog names that signal both the mechanism and the underlying compound. Researchers comparing supplier offerings will encounter "retatrutide," "GLP-3 RT," "GLP-3 R," "RT peptide," and a dozen other typographic variants that all point to the same molecule.
Why Naming Conventions Matter for Sourcing
If GLP-3 RT and retatrutide are the same compound, why does the labeling matter? Because in the research peptide market, the name on the catalog is one of several signals about how a supplier handles regulatory framing, documentation, and quality. A reliable supplier explicitly maps the catalog name to the underlying INN, includes both names in product documentation, and provides a Certificate of Analysis that references the molecule's structural features (sequence, fatty acid acylation, molecular weight) without ambiguity.
Suppliers that use only proprietary catalog names without disclosing the underlying INN raise reasonable questions about transparency. A researcher comparing analytical results between batches, between suppliers, or against published preclinical literature needs to be able to confirm that the molecule under study matches the reference identity. Without the INN linkage, that comparison becomes uncertain.
The good news is that GLP-3 RT is a well-established naming convention with broad recognition. Midwest Peptide's product page for GLP-3 RT (Retatrutide) explicitly leads with both names and lists every common typographic variant (GLP3RT, GLP-3-RT, RT peptide, GLP3-RT) so that researchers searching under any of these names land on the same canonical product. This kind of disclosure-first naming is one of the criteria that distinguishes reliable research peptide suppliers from less transparent ones.
How GLP-3 RT Differs From GLP-1 and GLP-2 in Research Catalogs
The "GLP-3" designation in GLP-3 RT is best understood as a generational marker rather than a strict pharmacological class. In the broader incretin research peptide landscape, three categories of catalog names are common:
- GLP-1 SM (Semaglutide). A long-acting GLP-1 receptor agonist with a fatty-acid side chain enabling albumin binding. Single-receptor target. The SM suffix derives from semaglutide.
- GLP-2 TZ (Tirzepatide). A dual GLP-1/GIP receptor agonist with a fatty-acid modification for extended half-life. Two-receptor target. The TZ suffix derives from tirzepatide.
- GLP-3 RT (Retatrutide). A triple GLP-1/GIP/glucagon receptor agonist. Three-receptor target. The RT suffix derives from retatrutide.
The numbers (GLP-1, GLP-2, GLP-3) reflect the count of receptors targeted, not three separate endogenous peptide classes. There is no endogenous "GLP-3" hormone; the name reflects the molecule's research positioning as the third-generation triple-agonist successor to single-target and dual-target incretin research peptides. For a deeper look at where each fits in the research literature, see GLP-3 RT in Research: A Triple GLP-1/GIP/Glucagon Receptor Agonist Literature Review and Dual vs Triple Incretin Agonists: Comparative Research Literature.
What the Triple Agonist Mechanism Means in Research Models
The reason retatrutide attracted research interest beyond the dual-agonist class is the addition of glucagon receptor agonism. GLP-1 and GIP receptor activation drive integrated incretin effects on insulin secretion, food intake, and adipose tissue handling. Glucagon receptor activation in liver hepatocytes drives gluconeogenesis, increases hepatic energy expenditure through futile metabolic cycling, and supports lipid oxidation.
In a single molecule that activates all three receptors with carefully balanced potencies, the glucose-lowering effects of GLP-1 and GIP outweigh the glucose-raising tendency of glucagon receptor activation while preserving the energy-expenditure and hepatic-lipid benefits that glucagon agonism contributes. The net effect in published preclinical research is greater body weight reduction in diet-induced obese rodent models than either single or dual agonists at matched doses, with body composition shifts that preferentially reduce adipose mass while preserving lean mass.
This is why the molecule sits at the leading edge of incretin agonist development and why research labs actively work with the GLP-3 RT version of the compound. Energy expenditure and body composition endpoints in rodent studies have been published in major peer-reviewed venues and continue to expand. For a focused look at the energy expenditure endpoints, see Retatrutide Energy Expenditure Research: Thermogenesis Animal Model Studies. For hepatic lipid handling, Retatrutide Lipid Profile Research: Hepatic Steatosis Literature is the cluster reference.
Verifying GLP-3 RT Identity in Practice
Once a researcher accepts that GLP-3 RT and retatrutide are the same molecule, the next practical question is how to verify identity on a specific batch. Three analytical pillars apply:
HPLC purity above 98 percent. High-performance liquid chromatography separates the target peptide from related impurities (deletion sequences, truncated chains, oxidation products) and quantifies the main peak as a percentage of total UV absorbance at 220 nm. The clinical retatrutide reference and the research-grade GLP-3 RT supplied for in-vitro work should both show HPLC profiles dominated by a single peak above the 98 percent threshold.
Mass spectrometry molecular weight match. Retatrutide's theoretical molecular weight is approximately 4937 Da, accounting for the 39-amino-acid sequence and the C20 diacid fatty acid modification. A mass spectrometry result within tolerance of this value confirms that the synthesized material is the correct sequence and that the fatty acid modification is intact. A mass that comes in low suggests the modification is missing; a mass that comes in significantly off-target suggests sequence errors.
Peptide content quantification. The COA should report not just purity but the actual peptide content as a percentage of the total mass in the vial. A 10 mg vial of GLP-3 RT should contain a quantified mass of retatrutide peptide, with the remainder being counter-ions, residual solvents, and (in lyophilized formulations) bulking agents. Without this quantification, researchers cannot calculate accurate concentrations from the labeled vial mass.
For background on how mass spectrometry confirms peptide identity in research bioanalysis, the peptide bioanalysis research guide walks through the LC-MS methodology in more depth.
External Research References for GLP-3 RT
Researchers wanting authoritative external context for retatrutide pharmacology can consult several non-commercial resources. The retatrutide clinical pharmacology summary on Wikipedia provides an accessible overview of the published trial data and INN history. The Endocrine Society publishes peer-reviewed coverage of incretin pharmacology and metabolic research relevant to the triple-agonist class. Peer-reviewed primary research on receptor pharmacology and preclinical models is published in journals indexed at ScienceDirect and Nature Medicine.
Sourcing GLP-3 RT for Research
Once GLP-3 RT identity is confirmed against the retatrutide reference, the operational question is sourcing. A reliable supplier provides batch-specific COAs, HPLC and mass spectrometry data on every lot, transparent fatty acid modification disclosure, and consistent fulfillment. Midwest Peptide ships GLP-3 RT (Retatrutide) with each of these as the standard inclusion. The accompanying Where to Buy Retatrutide (GLP-3 RT) for Research: Sourcing Guide walks through the supplier evaluation criteria in detail. For broader supplier reliability framing across the research peptide market, the Most Reliable Peptide Company sourcing guide lays out the seven criteria that distinguish dependable from unreliable vendors.
Bottom Line
GLP-3 RT and retatrutide are two names for the same molecule. The name a research peptide is sold under matters less than the analytical documentation that verifies its identity. When evaluating any retatrutide-class research peptide, focus on the batch-specific COA, the HPLC and mass spectrometry results, and the supplier's transparency about the underlying INN. A reliable supplier will explicitly map the catalog name to retatrutide, provide complete analytical disclosure, and consistently deliver material that matches the reference molecule across batches.
For research-grade GLP-3 RT (Retatrutide) with batch-specific COA, HPLC purity verification, and mass spectrometry identity confirmation, see the GLP-3 RT product page and the Midwest Peptide research catalog. All products are supplied strictly for laboratory and in-vitro research use only. Not for human consumption.
Related Research Reading
Within the cluster:
- Pillar: GLP-3 RT in Research: A Triple GLP-1/GIP/Glucagon Receptor Agonist Literature Review
- Triple Incretin Receptor Activation: GLP-1, GIP, and Glucagon Combined Mechanism
- Glucagon Receptor in Triagonist Research: Energy Expenditure Pathways
- Retatrutide Energy Expenditure Research: Thermogenesis Animal Model Studies
- Retatrutide Lipid Profile Research: Hepatic Steatosis Literature
- Dual vs Triple Incretin Agonists: Comparative Research Literature
- Comparative Analysis: GLP-3 RT vs. Traditional GLP-Class Peptides
- Where to Buy Retatrutide (GLP-3 RT) for Research: Sourcing Guide
- Most Reliable Peptide Company: A Researcher's 2026 Sourcing Guide
